Ampliphi Biosciences Corp (NYSEMKT:APHB) a global leader in the advancement of bacteriophage-based antibacterial treatments to cure drug-resistant infections, reported that Peter-John Wormald, MD, commented on the promising report from the Phase 1 study of AB-SA01 in subjects with chronic rhinosinusitis.
In December 2016, AmpliPhi Biosciences reported that AB-SA01, its investigational bacteriophage cocktail aiming Staphylococcus aureus infections, fulfilled the Phase 1 study’s primary objectives of tolerability and safety in subjects who had not responded to standard of care treatment, comprising previous sinus surgery. In addition, all nine subjects registered in the study witnessed a decline in the number of S. aureus infecting sinuses, with some subjects showing complete removal of the bacterial infection.
Dr. Peter-John Wormald, the Principal Investigator, said that he is delighted with the data of this groundbreaking phage trial in subjects suffering from CRS. He has long considered that phage treatment has the potential to cure recalcitrant infections in the part of CRS subjects who fail conventional treatment.
They have noted considerable improvements in symptoms scores as well as on nasal endoscopy offering evidence of the effectiveness of phage treatment. Grounded on his experience curing these patients and the results he has noted in this trial phage therapy requires continued assessment as a means to cure CRS subjects whose infections return after sinus surgery.
- Scott Salka, the CEO of AmpliPhi Biosciences, reported that they saw decline in S. aureus bacterial load in subjects cured with AB-SA01 in Phase 1 study, which is particularly promising since most subjects also confirmed improvements in symptoms. CRS is a grave condition with subjects posting quality-of-life scores that are mainly worse than those facing chronic back pain or congestive heart failure. A projected 300,000 sinus surgeries are carried out in the U.S. for this condition with the recurrence noted in almost 20% of patients’ post-surgery.